AbbVie (ABBV) and Pfizer (PFE) are under the spotlight as two prominent healthcare stocks for dividend-seeking investors. AbbVie, with a yield of 3.2%, has demonstrated robust dividend growth even after losing patent protection on its top drug, Humira. In contrast, Pfizer offers a higher yield of 6.7% but faces challenges with its growth trajectory and upcoming patent expirations, raising concerns about the sustainability of its dividend.
For market professionals, the crux of the investment decision lies in the safety of Pfizer’s dividend. Despite its higher yield, Pfizer’s payout ratio exceeds 100%, and its recent financial performance has been marred by restructuring costs and one-time charges. In comparison, AbbVie boasts a healthier free cash flow of nearly $20 billion, comfortably covering its dividend payments, suggesting a more secure investment for income-focused portfolios.
Ultimately, while Pfizer may attract risk-tolerant investors, AbbVie emerges as the safer choice for those prioritizing reliable dividend income and potential growth in payouts.
Source: fool.com